SCHEMBL3686281

SCHEMBL3686281

CCCC(C)CC(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.42
HSD17B10 Q99714 2/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CHRM1 P11229 1/20 0.36
AKR1A1 P14550 1/20 0.36
CHRM3 P20309 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8984909 0.90 TSHR (0.38) TSHRHSD17B10MGAMGAASI
SCHEMBL31011228 0.87 CA2 (0.47) TSHRHSD17B10CA1CA2TDP1
SCHEMBL10682889 0.87 CA2 (0.47) TSHRHSD17B10CA1CA2TDP1
SCHEMBL14651155 0.87 CA2 (0.47) TSHRHSD17B10CA1CA2TDP1
SCHEMBL13610030 0.85 ACE2 (0.48) HSD17B10CA1CA2BIRC2ZDHHC7
SCHEMBL1739273 0.84 TSHR (0.44) TSHRHDAC7HDAC8HDAC6HDAC9
SCHEMBL16201901 0.84 ACE2 (0.52) HSD17B10BIRC2ZDHHC7MEN1HPGD
SCHEMBL2254424 0.84 ACE2 (0.52) HSD17B10BIRC2ZDHHC7MEN1HPGD
SCHEMBL28333296 0.84 ACE2 (0.52) HSD17B10BIRC2ZDHHC7MEN1HPGD
SCHEMBL28851524 0.84 ACE2 (0.52) HSD17B10BIRC2ZDHHC7MEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108981-B2 Cyclic P1 linkers as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-08-18 US disclosed
US-20150057262-A1 CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS NAVY, SECRETARY OF THE UNITED STATES OF AMERICA 2015-02-26 US disclosed
US-8901115-B2 Cyclic P1 linkers as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-02 US disclosed
US-20140163002-A1 CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-06-12 US disclosed
CN-101880447-B Polyester polyol used for high-weatherability coil coating and preparation method thereof Zhangjiagang shunchang chemical co ltd 2013-05-01 CN disclosed
EP-1527038-B1 PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUDS LUCITE INT UK LTD (GB) 2010-03-17 EP disclosed
CN-1301955-C Process for the carbonylation of ethylenically unsaturated compouds LUCITE INT UK LTD (GB) 2007-02-28 CN disclosed
CN-1675160-A Process for the carbonylation of ethylenically unsaturated compouds LUCITE INT UK LTD (GB) 2005-09-28 CN disclosed
US-4775692-A ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT TORAY INDUSTRIES, INC. (JP) 1988-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057262-A1 CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS F11, F12, F13A1 TSHR 3059/4885HSD17B10 2893/4885MGAM 3588/4885
US-20140163002-A1 CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS F11, F12, F13A1 TSHR 3059/4885HSD17B10 2893/4885MGAM 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.